Novel Technologies Show Promise in AMD Treatment: Gene Therapy and Light-Based Interventions Take Center Stage
• Groundbreaking optogenetics gene therapy emerges as an innovative treatment approach for age-related macular degeneration, marking a significant advancement in eye care technology.
• Photobiomodulation therapy shows potential as a novel light-based treatment option for patients with dry AMD, expanding the therapeutic arsenal for this challenging condition.
• New developments in AMD detection include home monitoring devices and artificial intelligence integration, while Lacrifill emerges as a promising canalicular gel treatment for dry eye disease.
Leading experts are preparing to unveil cutting-edge technologies and treatments for various eye conditions at the upcoming Southeastern Educational Congress of Optometry (SECO) 2025 meeting, with a particular focus on revolutionary approaches to managing age-related macular degeneration (AMD).
Julie Rodman, OD, MS, FAAO, clinic chief at Nova Southeastern University College of Optometry, will present groundbreaking developments in AMD detection and treatment during her keynote address. The presentation will highlight several innovative technologies that promise to transform eye care delivery and patient outcomes.
The integration of artificial intelligence and home monitoring devices is revolutionizing how AMD is detected and tracked. These technological advances enable earlier intervention and more precise patient monitoring, potentially improving treatment outcomes for those affected by the condition.
A major highlight of the upcoming presentation is optogenetics, a novel gene therapy approach that has generated significant excitement in the ophthalmology community. This innovative therapeutic strategy represents a new frontier in genetic interventions for eye diseases, though specific efficacy data and treatment protocols are yet to be detailed.
Photobiomodulation emerges as a promising new therapeutic approach for dry AMD patients. This light therapy technique offers a non-invasive treatment option, potentially addressing an area of significant unmet need in AMD management. The technology's mechanism of action and preliminary results suggest it could become an important addition to the current treatment landscape.
Beyond AMD innovations, Rodman will also discuss Lacrifill, a new canalicular gel developed by Nordic Pharma. This novel treatment represents a departure from traditional dry eye therapies and shows promising potential for managing this common ocular condition.
The SECO 2025 meeting will feature interactive workshops where healthcare professionals can gain practical experience with these new technologies. These sessions aim to provide valuable hands-on training with the latest diagnostic and therapeutic devices, ensuring practitioners are well-equipped to implement these innovations in their clinical practice.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related Topics
Reference News
[1]
Cutting-Edge Eye Care Technologies Highlighted at SECO 2025
ajmc.com · Feb 28, 2025
[2]
SECO Keynote to Focus on Novel Technologies for Eye Conditions
ajmc.com · Feb 26, 2025
[3]
A Glimpse Into the Future of Eye Care at SECO 2025
ajmc.com · Feb 25, 2025